Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
160.26
+0.62 (0.39%)
At close: Dec 27, 2024, 4:00 PM
161.00
+0.74 (0.46%)
After-hours: Dec 27, 2024, 4:01 PM EST
Natera Revenue
Natera had revenue of $439.76M in the quarter ending September 30, 2024, with 63.90% growth. This brings the company's revenue in the last twelve months to $1.53B, up 54.94% year-over-year. In the year 2023, Natera had annual revenue of $1.08B with 31.99% growth.
Revenue (ttm)
$1.53B
Revenue Growth
+54.94%
P/S Ratio
12.73
Revenue / Employee
$465,216
Employees
3,293
Market Cap
21.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Koninklijke Philips | 20.12B |
Labcorp Holdings | 12.71B |
Biogen | 9.61B |
Zimmer Biomet Holdings | 7.60B |
STERIS | 5.33B |
Illumina | 4.39B |
The Cooper Companies | 3.90B |
BeiGene | 3.35B |
NTRA News
- 7 days ago - Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252% - Benzinga
- 10 days ago - Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics - Business Wire
- 15 days ago - Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer - Business Wire
- 18 days ago - Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment - Business Wire
- 25 days ago - Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology - Business Wire
- 4 weeks ago - Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients - Business Wire
- 4 weeks ago - Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium - Business Wire
- 4 weeks ago - Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™ - PRNewsWire